CLMT · Calumet, Inc.

Current Thesis

Calumet’s lower-cost sustainable aviation fuel expansion supports its re-rating if production exceeds 80 million gallons annually by year-end 2026 without an increase in the disclosed $137 million remaining-capital plan. Those are management’s 2026-09-01 milestones; a weekly close below $47 invalidates the market thesis before that operating test.

The material development since the 2026-09-05 assessment is completed financing: Montana Renewables received the final $34 million Department of Energy loan draw, Calumet disclosed on 2026-09-14. Receipt converts that part of the financing plan into an accomplished step; it does not establish the expansion’s eventual earnings. Calumet financing release.

The assessment remains that the narrative is accelerating — the 2026-09-14 funding receipt followed the September capital redesign, while the 2026-09-18 adjusted close reached $59.00 against a $59.05 52-week high. This is an inference from financing progress and price momentum, not a measurement of broader investor participation. The case remains a legacy refining business converting existing equipment into renewable-fuel production.

Bullish and bearish views on Calumet, Inc.

The model's bull view on Calumet, Inc. (CLMT), in brief: The capital requirement is smaller. Management’s 2026-09-01 redesign specified $137 million of remaining expansion capital against the $1.2 billion project originally contemplated. Repurposing adjacent refining equipment is the stated mechanism; the figure remains a project… The bear view: Consolidated losses remain material. The 2026-08-07 results reported a second-quarter net loss of $95.9 million and a six-month net loss of $412.9 million. Financing progress alone does not resolve that earnings record. The redesign reduces expected benefits. On 2026-09-01… Both cases follow in full.

Bull Case

• The capital requirement is smaller. Management’s 2026-09-01 redesign specified $137 million of remaining expansion capital against the $1.2 billion project originally contemplated. Repurposing adjacent refining equipment is the stated mechanism; the figure remains a project estimate, not completed expenditure.
• Compliance relief has been specified. Calumet’s 2026-09-02 release reported exemptions removing 71 million Renewable Identification Numbers (RINs), valued at approximately $170 million, for the 2025 compliance year. This is relief from an obligation; the announcement does not establish a cash receipt of that amount.
• Production has a dated test. The 2026-09-01 plan targeted an annual sustainable aviation fuel run-rate above 80 million gallons at year-end 2026, following the reported 60 million-gallon annual run-rate in spring 2026. Delivery within the disclosed capital plan would substantiate the operating thesis.

Bear Case

• Consolidated losses remain material. The 2026-08-07 results reported a second-quarter net loss of $95.9 million and a six-month net loss of $412.9 million. Financing progress alone does not resolve that earnings record.
• The redesign reduces expected benefits. On 2026-09-01, management described the revised project as capturing approximately 70% of the originally expected benefit for 15% of the originally expected Phase 2 capital. The smaller capital requirement therefore accompanies a smaller anticipated operating benefit.
• Credit commitments are conditional liquidity. The 2026-09-14 amendment increased revolving-credit commitments to $600 million, subject to borrowing-base limitations. Management attributed the adjustment to higher market prices and receivables; commitments do not establish unrestricted cash availability. Calumet financing release.

Setup & Price Structure

The measured price record for 2026-09-18 shows a $59.00 adjusted close, a three-month increase of 77.4%, and a 14-period relative strength index (RSI) of 94.7. The close was 0.1% below the $59.05 52-week high. These observations establish strong momentum; they do not identify who owns the shares or establish when momentum reverses.

The observable attention cluster includes the H.C. Wainwright conference scheduled for 2026-09-15 and newly announced T.D. Cowen meetings on 2026-09-24. Conference scheduling is evidence of investor outreach, not proof of retail crowding. No quantified fund-flow, short-interest, insider-sale or moving-average evidence accompanies the current price record. Calumet announcements.

The $47 thesis-break threshold corresponds to UBS’s 2026-08-25 analyst target and preserves the prior published invalidation condition. An analyst valuation is not demonstrated chart support. H.C. Wainwright’s separately reported 2026-09-02 target was $75; neither target establishes a forecast outcome for this dossier.

Catalyst Calendar (next 30 days)

• 2026-09-24 — T.D. Cowen Energy Conference. Calumet’s 2026-09-17 announcement schedules one-on-one investor meetings. Any public revision to expansion costs or timing would bear directly on the thesis; the meeting itself does not verify production progress. Calumet event listing.
• 2026-12-31 — Decisive operating checkpoint. Beyond the next 30 days, this is the year-end deadline implied by management’s 2026-09-01 plan for the fourth-quarter equipment tie-in and an annual sustainable aviation fuel run-rate above 80 million gallons. It is an operating deadline, not an announced results-release date.

What Would Change Our Mind

Failure to deliver the cheaper expansion would break the operating argument: a disclosed increase above the 2026-09-01 remaining-capital estimate of $137 million, a tie-in delayed into 2027, or a year-end 2026 annual production run-rate at or below 80 million gallons would contradict the stated case. Independently, a weekly close below $47 would invalidate the market thesis.

Confirmation requires reported operating delivery, rather than another financing announcement. Management’s production milestone and capital estimate provide observable tests; the 2026-09-14 loan receipt satisfies only the identified funding step.

Correlation Notes

This is a single-name execution thesis, with no measured peer-group correlation established by the available evidence. Calumet’s 2026-09-02 exemption disclosure identifies a direct regulatory exposure, while the 2026-08-07 results show the continuing importance of the legacy business: Specialty Products & Solutions generated $161.7 million of second-quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) with tax attributes, versus $26.6 million for Montana/Renewables. Those segment figures describe business exposures; they do not establish stock-price correlation with crude oil or clean-energy equities.